Exicure, Inc.

NasdaqCM XCUR

Exicure, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024

Exicure, Inc. Gross Profit is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Exicure, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 7.77 M.
Exicure, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -13.71 M, a -4.71% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: XCUR

Exicure, Inc.

CEO	Mr. Paul Kang
IPO Date	May 22, 2018
Location	United States
Headquarters	2430 North Halsted Street
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years